Background
tumor, PDAC, pancreatic ductal adenocarcinoma
PANCREATIC DUCTAL ADENOCARCINOMA, TUMOR
In preclinical pancreatic ductal adenocarcinoma (PDAC) models, inhibition of hepatocyte growth factor (HGF) signaling using ficlatuzumab, a recombinant humanized anti-HGF antibody, and gemcitabine reduced tumor burden.